Seaport Therapeutics shares Phase 1 PK data for GlyphAgo at ECNP

October 9, 2026 1:00 PM

Seaport Therapeutics (Nasdaq: SPTX), a clinical-stage neuropsychiatric drug developer and founded entity of PureTech Health (LSE: PRTC), presented Phase 1 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found